Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Larimar Therapeutics, Inc.

Clinical trials sponsored by Larimar Therapeutics, Inc., explained in plain language.

Upcoming readouts

Trials from this sponsor expected to report results within the next 12 months.

Hope for Friedreich's ataxia: new drug trial aims to slow disease progression Results expected Jan 2027 (estimated)

Browse trials soon ready across all sponsors →

Trials to join now! 2 Terminated 1

Experimental Friedreich's ataxia drug tested in kids – but trial halted early

Disease control Stopped early

This early-stage trial tested a drug called nomlabofusp (CTI-1601) in 18 adolescents and children with Friedreich's ataxia, a rare genetic disease that affects movement and coordination. The goal was to check safety and how the body processes the drug. However, the study was term…

Phase 1 • Sponsor: Larimar Therapeutics, Inc. • Aim: Disease control

Last updated Jul 12, 2026 00:00 UTC